American Century Companies Inc. Has $2.69 Million Position in Supernus Pharmaceuticals Inc (SUPN)

Share on StockTwits

American Century Companies Inc. boosted its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1.3% in the fourth quarter, HoldingsChannel reports. The firm owned 81,048 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,001 shares during the quarter. American Century Companies Inc.’s holdings in Supernus Pharmaceuticals were worth $2,692,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. BlackRock Inc. raised its stake in Supernus Pharmaceuticals by 0.9% during the fourth quarter. BlackRock Inc. now owns 8,075,659 shares of the specialty pharmaceutical company’s stock worth $268,272,000 after acquiring an additional 72,658 shares in the last quarter. Vanguard Group Inc raised its stake in Supernus Pharmaceuticals by 3.2% during the third quarter. Vanguard Group Inc now owns 5,116,478 shares of the specialty pharmaceutical company’s stock worth $257,614,000 after acquiring an additional 160,765 shares in the last quarter. Vanguard Group Inc. raised its stake in Supernus Pharmaceuticals by 3.2% during the third quarter. Vanguard Group Inc. now owns 5,116,478 shares of the specialty pharmaceutical company’s stock worth $257,614,000 after acquiring an additional 160,765 shares in the last quarter. Glenmede Trust Co. NA raised its stake in Supernus Pharmaceuticals by 52.2% during the third quarter. Glenmede Trust Co. NA now owns 993,483 shares of the specialty pharmaceutical company’s stock worth $50,020,000 after acquiring an additional 340,677 shares in the last quarter. Finally, Fiera Capital Corp raised its stake in Supernus Pharmaceuticals by 6.0% during the fourth quarter. Fiera Capital Corp now owns 941,530 shares of the specialty pharmaceutical company’s stock worth $31,277,000 after acquiring an additional 53,404 shares in the last quarter. 99.18% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have commented on the company. Piper Jaffray Companies set a $44.00 target price on Supernus Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, January 16th. ValuEngine downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Cantor Fitzgerald reissued a “buy” rating and set a $57.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 27th. BidaskClub raised Supernus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 4th. Finally, Mizuho boosted their target price on Supernus Pharmaceuticals from $61.00 to $63.00 and gave the stock a “buy” rating in a research note on Monday, December 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $55.75.

NASDAQ:SUPN opened at $37.72 on Tuesday. The stock has a market cap of $1.98 billion, a PE ratio of 18.40 and a beta of 1.59. The company has a current ratio of 3.06, a quick ratio of 2.90 and a debt-to-equity ratio of 0.73. Supernus Pharmaceuticals Inc has a 1-year low of $30.05 and a 1-year high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.19. The company had revenue of $113.50 million for the quarter, compared to analysts’ expectations of $105.36 million. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. The business’s quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.26 earnings per share. As a group, sell-side analysts anticipate that Supernus Pharmaceuticals Inc will post 2.37 earnings per share for the current year.

In other news, CFO Gregory S. Patrick sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total transaction of $830,600.00. Following the sale, the chief financial officer now directly owns 67,896 shares in the company, valued at $2,819,720.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://macondaily.com/2019/04/16/american-century-companies-inc-has-2-69-million-position-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.